Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course

Lymphoma, Large B-Cell, Diffuse

NGR-hTNF

RITUXIMAB

Doxorubicin

Cyclophosphamide

Vincristine

Prednisone

Ospedale San Raffaele

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Activity in terms of overall response rate (ORR): Complete Response (CR) and Partial Response (PR) of R-CHOP21 chemo-immunotherapy preceded by BBBP by NGR-hTNF.

DOR will be assessed for all responsive patients; time to documentation of tumor response to failure

PFS will be assessed for all treated patients; it is defined as the interval between the time of entry onto trial and failure (relapsing or progressive disease), death from any cause or date of the last visit of follow-up

OS will be assessed for all enrolled patients; it is defined as the time from entry onto trial until death from any cause or date of the last visit of follow-up.

Tolerability will be assessed for all enrolled patients; it is defined by of grade 3-4 AEs according to NCI CTCAE.

Andres J. M. Ferreri

Principal Investigator

MolMed S.p.A.

Patients will receive NGR-hTNF at dose of 0.8 mcg/sqm 1 hour before standard R-CHOP (cyclophosphamide-doxorubicin-vincristine-prednisone-rituximab) regimen every 3 weeks for six courses (except for course #1 in which only standard R-CHOP regimen will be administered)

Congenital Solitary Kidney

Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi,

Long Term Outcome of Congenital Solitary Kidney

Renal Outcome in Children With Congenital Solitary Kidney: a Longitudinal Prognostic Study

Chronic kidney disease defined by National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents with a glomerular filtration rate less than 89 ml/min/1.73 m2.

Proteinuria defined by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative as a urine protein/urine creatinine ratio of more than 0.5 in children younger six months and of more than 0.2 in older children.

Hypertension defined by the National High Blood Pressure Education Program Working Group as a blood pressure ≥ 95th percentile

triamine/syöpä

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Long Term Outcome of Congenital Solitary Kidney

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Täydellisin lääketieteellinen tietokanta tieteen tukemana